Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced a multi-year plan for a new, purpose-built, high-tech facility for its Central Laboratory Services (CLS) operations in Brownsburg, Indiana. Operations from our current Indianapolis site will transition to the new facility, enabling an expansion of overall capacity. The strategic investment is designed to accelerate growth, enhance operational efficiency, expand the company's lab footprint and kit production capabilities, and strengthen its ability to deliver integrated, technology-driven laboratory services to customers and patients worldwide.
“This expansion marks an exciting new chapter for Labcorp’s Central Laboratories Services,” said Megan Bailey, EVP and President, Central Laboratory Services and International, Labcorp. “We’re investing in capabilities and resources to advance science, drive innovation and scale our operations to meet customer demand—ultimately enabling us to transform lab and clinical trial services by delivering more integrated, connected experiences for sponsors, sites and patients.”
“Life sciences are growing as an important sector of the Indiana economy, and this significant investment by Labcorp is an exciting new development in that story that will create additional well-paying jobs. Indiana supports innovation and growth in the life sciences sector, and our state is the ideal place for those companies to build and expand,” said Indiana Governor Mike Braun.
An Expanded Footprint to Advance Science
Labcorp’s new 50-acre campus in Brownsburg will feature more than 500,000 square feet of advanced laboratory and production space—expanding the company’s current Indianapolis facility footprint by 40%. The site will include CLS laboratories, kit production operations, bioanalytical (BioA) services and the company’s Indianapolis Diagnostics branch. Engineered for scalability and innovation, the facility will incorporate cutting-edge infrastructure and digital technologies to support Labcorp’s growing portfolio and accelerate global drug development.
Advancing a Proven Legacy of Clinical Trial Support
Over the past five years, Labcorp CLS has supported more than 5,000 clinical trial protocols involving patients across more than 100 countries, powered by five globally integrated labs in Indianapolis, Geneva, Singapore, Shanghai and Kawagoe City. The new facility will build on this foundation, using automation, data analytics and smart lab technologies to deliver even faster clinical insights.
Building the Future in Brownsburg
Labcorp selected Brownsburg—just six miles from the company’s current location—for its strategic location near major highways, the Indianapolis International airport, downtown Indianapolis and key distribution centers. Construction is scheduled to begin in the second half of 2026, with completion targeted for early 2030.
“The decision by Labcorp to build their new Central Laboratory Services facility in Brownsburg is a landmark moment for our community,” said Town Council President Ben Lacey. “We are proud to partner with a company dedicated to improving lives for people around the world. The innovative work that will happen at this facility will create significant job opportunities and positions Brownsburg as a hub for life science and healthcare development.”
About Labcorp
Labcorp (NYSE: LH) is a global leader of innovative and comprehensive laboratory services that helps doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. We provide insights and advance science to improve health and improve lives through our unparalleled diagnostics and drug development laboratory capabilities. The company's nearly 70,000 employees serve clients in approximately 100 countries, provided support for 75% of the new drugs and therapeutic products approved in 2024 by the FDA, and perform more than 700 million tests annually for patients around the world. Learn more about us at www.labcorp.com.
Cautionary Statement Regarding Forward-Looking Statements This press release contains forward-looking statements, including, but not limited to, statements with respect to the company’s plans for, and the expected benefits to result from, a new Central Laboratory Services facility in Brownsburg, Indiana.
Each of the forward-looking statements is subject to change based on various important factors, many of which are beyond the company's control. These factors, in some cases, have affected and in the future (together with other factors) could affect the company's ability to implement the company's business strategy, and actual results could differ materially from those suggested by these forward-looking statements. As a result, readers are cautioned not to place undue reliance on any of the forward-looking statements.
The company has no obligation to provide any updates to these forward-looking statements even if its expectations change. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. Further information on potential factors, risks and uncertainties that could affect operating and financial results is included in the company's most recent Annual Report on Form 10-K under the heading RISK FACTORS and in the company's other filings with the SEC. The information in this press release should be read in conjunction with a review of the company's filings with the SEC including the information in the company's most recent Annual Report on Form 10-K under the heading "MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS".
Labcorp’s new 50-acre campus in Brownsburg will feature more than 500,000 square feet of advanced laboratory and production space—expanding the company’s current Indianapolis facility footprint by 40%. The site will include CLS laboratories, kit production operations, bioanalytical (BioA) services and the company’s Indianapolis Diagnostics branch. Engineered for scalability and innovation, the facility will incorporate cutting-edge infrastructure and digital technologies to support Labcorp’s growing portfolio and accelerate global drug development.
Advancing a Proven Legacy of Clinical Trial Support
Over the past five years, Labcorp CLS has supported more than 5,000 clinical trial protocols involving patients across more than 100 countries, powered by five globally integrated labs in Indianapolis, Geneva, Singapore, Shanghai and Kawagoe City. The new facility will build on this foundation, using automation, data analytics and smart lab technologies to deliver even faster clinical insights.
Building the Future in Brownsburg
Labcorp selected Brownsburg—just six miles from the company’s current location—for its strategic location near major highways, the Indianapolis International airport, downtown Indianapolis and key distribution centers. Construction is scheduled to begin in the second half of 2026, with completion targeted for early 2030.
“The decision by Labcorp to build their new Central Laboratory Services facility in Brownsburg is a landmark moment for our community,” said Town Council President Ben Lacey. “We are proud to partner with a company dedicated to improving lives for people around the world. The innovative work that will happen at this facility will create significant job opportunities and positions Brownsburg as a hub for life science and healthcare development.”
About Labcorp
Labcorp (NYSE: LH) is a global leader of innovative and comprehensive laboratory services that helps doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. We provide insights and advance science to improve health and improve lives through our unparalleled diagnostics and drug development laboratory capabilities. The company's nearly 70,000 employees serve clients in approximately 100 countries, provided support for 75% of the new drugs and therapeutic products approved in 2024 by the FDA, and perform more than 700 million tests annually for patients around the world. Learn more about us at www.labcorp.com.
Cautionary Statement Regarding Forward-Looking Statements This press release contains forward-looking statements, including, but not limited to, statements with respect to the company’s plans for, and the expected benefits to result from, a new Central Laboratory Services facility in Brownsburg, Indiana.
Each of the forward-looking statements is subject to change based on various important factors, many of which are beyond the company's control. These factors, in some cases, have affected and in the future (together with other factors) could affect the company's ability to implement the company's business strategy, and actual results could differ materially from those suggested by these forward-looking statements. As a result, readers are cautioned not to place undue reliance on any of the forward-looking statements.
The company has no obligation to provide any updates to these forward-looking statements even if its expectations change. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. Further information on potential factors, risks and uncertainties that could affect operating and financial results is included in the company's most recent Annual Report on Form 10-K under the heading RISK FACTORS and in the company's other filings with the SEC. The information in this press release should be read in conjunction with a review of the company's filings with the SEC including the information in the company's most recent Annual Report on Form 10-K under the heading "MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS".